Qian Jiang, vice president of Eli Lilly China Anti-Tumor Division, resigned Yin Hang, head of breast tumor line, to take over

A few days ago, Eli Lilly China President and General Manager Ji Liwen announced to employees that Qian Jiang, the current vice president of Eli Lilly China Anti-Tumor Division, decided to leave the company to seek external career development opportunities, and the last working day was the 29th of this month.

On the same day, Eli Lilly China also announced its successor after Qian Jiang, yin Hang, the current head of the breast tumor line of Eli Lilly China's anti-tumor business unit, will be promoted to vice president of the anti-tumor business unit, effective August 1, directly reported to Eli Lilly China President and General Manager Ji Liwen, and become a member of the Eli Lilly China Management Committee.

According to the data, Qian Jiang officially joined Eli Lilly on June 1, 2018 as the vice president of Eli Lilly China Anti-Tumor Division. Prior to joining Eli Lilly, Qian Jiang was executive director of Novartis Oncology (China) and head of the Solid Tumor Division. Prior to that, Qian Jiang worked as a product manager at Roche, a senior product manager at Merck&T, and joined Pfizer in 2005, successively serving as Pfizer China Market Manager, General Manager of Pfizer China Anti-Tumor Division, and Head of Business Liaison of global clinical development and medical affairs team at Pfizer Headquarters.

Yin Hang joined Eli Lilly China in 2019, initially as Marketing Director of the Anti-Oncology Division, and was later appointed Sales Director of Ayute North, and in November last year, Yin Hang became the Head of the Breast Tumor Line of the Anti-Tumor Division. Prior to that, he worked at Novo Nordisk.

Source: Medical representative